<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_vm9DZW2">Topical Collection -Digital Hypertension Digital health, digital medicine, and digital therapeutics in cardiology: current evidence and future perspective in Japan</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Â© The Author(s) 2023. This article is published with open access</p>
				</availability>
				<date type="published" when="2023-05-31">31 May 2023</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Akihiro</forename><surname>Nomura</surname></persName>
							<email>anomura@med.kanazawa-u.ac.jp</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> College of Transdisciplinary Sciences for Innovation , Kanazawa University , Kanazawa , Japan</note>
								<orgName type="department">College of Transdisciplinary Sciences for Innovation</orgName>
								<orgName type="institution">Kanazawa University</orgName>
								<address>
									<settlement>Kanazawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Cardiovascular Medicine , Kanazawa University Graduate School of Medical Sciences , Kanazawa , Japan</note>
								<orgName type="department">Department of Cardiovascular Medicine</orgName>
								<orgName type="institution">Kanazawa University Graduate School of Medical Sciences</orgName>
								<address>
									<settlement>Kanazawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Frontier Institute of Tourism Sciences , Kanazawa University , Kanazawa , Japan</note>
								<orgName type="department">Frontier Institute of Tourism Sciences</orgName>
								<orgName type="institution">Kanazawa University</orgName>
								<address>
									<settlement>Kanazawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Biomedical Informatics , CureApp Institute , Karuizawa , Japan</note>
								<orgName type="department">Department of Biomedical Informatics</orgName>
								<orgName type="institution">CureApp Institute</orgName>
								<address>
									<settlement>Karuizawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_SBvXFzz">Topical Collection -Digital Hypertension Digital health, digital medicine, and digital therapeutics in cardiology: current evidence and future perspective in Japan</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2023-05-31">31 May 2023</date>
						</imprint>
					</monogr>
					<idno type="MD5">191A79208E4983068F144CCBDC7E5A11</idno>
					<idno type="DOI">10.1038/s41440-023-01317-8</idno>
					<note type="submission">Received: 28 February 2023 / Accepted: 21 April 2023 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T10:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_ufwAPjc">Digital health</term>
					<term xml:id="_3xNUJDz">Digital medicine</term>
					<term xml:id="_9W9Q93g">Digital therapeutics</term>
					<term xml:id="_ExBpnfc">mHealth</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_2gEXWx2"><p xml:id="_7WJvw8y"><s xml:id="_aapqdRr">Ten years passed since Japan set out the Action Plan of Growth Strategy that declared the initiatives of digitalization for medicine, nursing care, and healthcare to achieve the world's most advanced medical care.</s><s xml:id="_VUYXwzd">The initiatives formed the foundation of the Japanese national strategy and have been continuously refined, resulting in the current environment of digital health and digital medicine.</s><s xml:id="_snmXn2B">Digital health-related terminologies are organized, such as "digital health," "digital medicine," and "digital therapeutics" (DTx), as well as several common digital technologies, including artificial intelligence, machine learning, and mobile health (mHealth).</s><s xml:id="_ZFvYFEe">DTx is included in mHealth and is a novel disease treatment option.</s><s xml:id="_FMHD4wq">Also, this article thoroughly describes DTx in Japan and compares it with those in the US and Germany, the leading countries in digital health-related policies, regulations, and their development status.</s><s xml:id="_wVVyY9T">In Japan, two of three DTx applications that have been approved and reimbursed by the Ministry of Health, Labor, and Welfare are explained in detail in relation to cardiovascular medicine.</s><s xml:id="_qmjdpcc">When added to a standard smoking cessation program, the DTx system for nicotine dependence significantly improved the continuous abstinence rate.</s><s xml:id="_qMTMTCg">Moreover, the DTx for hypertension together with the guideline-based hypertension management was effective in patients aged 65 years or younger who were diagnosed with essential hypertension without antihypertensive agents, and it was also found to be cost-effective.</s><s xml:id="_4nS5KCg">DTx in cardiovascular medicine, with consideration on safety, efficacy, and cost-effectiveness, could be widely used not only through basic experiments and clinical studies but also through social implementation.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_BgRmg7z">Introduction</head><p xml:id="_e7prD2B"><s xml:id="_r2Jr8RF">Almost 10 years ago, Japan set out the Action Plan of Growth Strategy that declared the initiatives of digitalization for medicine, nursing care, and healthcare to achieve the world's most advanced medical care.</s><s xml:id="_bD3PY3S">This action promoted a major push for digital health and digital medicine in Japan.</s><s xml:id="_y8qxqhX">Specific plans included the following: (1) construction of a digital infrastructure for medicine, nursing care, and healthcare; (2) utilization of the digital infrastructure; (3) advanced digitalization of on-site operations; and (4) system establishment for utilizing medical and personal information.</s><s xml:id="_XQqRPHT">These initiatives formed the foundation of the Japanese national strategy and have been continuously refined, resulting in the current environment of digital health and digital medicine <ref type="bibr">[1]</ref>.</s></p><p xml:id="_3R9gNnP"><s xml:id="_uncKDdN">In this article, we define digital health-related terminologies.</s><s xml:id="_EFwNQdQ">First, "digital health" is a comprehensive concept of the utilization of information and communication technology (ICT) for all medical, nursing care, or healthcare support.</s><s xml:id="_a8V5MSe">ICT includes digital technologies such as medical big data of genomic and electronic health information, artificial intelligence (AI), or extended reality (XR) <ref type="bibr" target="#b0">[2]</ref>.</s><s xml:id="_zAhDkCv">This term often implies the use of the latest and state-of-the-art digital technology to solve various problems in healthcare fields as the objective.</s><s xml:id="_7pNSPEJ">Digital technology seems well suited in the following fields: patient treatment; health promotion including primary prevention; the conduct and support of clinical research including decentralized clinical trials; medical education; observation and evaluation of the patients' clinical course; and public health monitoring for the general population or specific disease cohorts.</s><s xml:id="_NrdcV6x">Moreover, "digital medicine" refers to digital health related to medical care and broadly supporting medicine practice."</s><s xml:id="_ZZd6u93"><ref type="bibr" target="#b1">[3]</ref> In digital medicine, the use of digital technology for disease treatment is referred to as "digital therapeutics (DTx)" (Fig. <ref type="figure" target="#fig_0">1</ref>) <ref type="bibr" target="#b2">[4]</ref>.</s></p><p xml:id="_BGMaSMQ"><s xml:id="_mRt6YpD">For years, various studies and clinical applications other than digital technologies have been conducted to solve healthcare issues.</s><s xml:id="_Pym2bFs">However, digital technology has become one of the powerful tools to solve healthcare-related problems in any medical field and has strongly assisted the evolution of digital health, along with the recent leap in ICT development, miniaturization and technical advantages of mobile devices, easy access to vast and organized data and ample computational resources, and establishment of 5th (5 G) or higher-generation mobile communication systems that allow for high-capacity, low-latency, and multiple connections.</s><s xml:id="_AEebnPU">Typical digital technologies include online medical services, AI and machine learning (AI/ML), Web 3.0 (web3) and blockchain technology, XR including metaverse, electronic health records (EHR) and personal health records (PHR), and mobile health (mHealth).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FJJEuaj">Telehealth and telemedicine</head><p xml:id="_F7tsqBs"><s xml:id="_FPjPJWd">As for online medical service, the Ministry of Health, Labour, and Welfare (MHLW) in Japan has provided "the guidance for the appropriate implementation of telemedicine."</s><s xml:id="_RKd5uaW"><ref type="bibr" target="#b3">[5]</ref> In this guidance, telehealth refers to health promotion and medically related activities using ICT equipment <ref type="bibr" target="#b3">[5]</ref>.</s><s xml:id="_rWbfQy2">It includes not only telemedicine but also online medical advice, remote healthcare communication, and real-time online consultation between physicians, similar in concept to digital health.</s><s xml:id="_PXxEQZH">In particular, telemedicine is strictly defined as real-time examination, diagnosis, explanation of laboratory results, and treatment Digital health, digital medicine, and digital therapeutics in cardiology: current evidence and future. . .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MNqet9s">Graphical Abstract</head><p xml:id="_9DKVWYN"><s xml:id="_tem6txP">between the physician and the patient, using remote communication tools installed on mobile devices or computers <ref type="bibr" target="#b3">[5]</ref>.</s><s xml:id="_X9qgfhE">Of note, regardless of whether it is an insurancecovered medical treatment or not, telemedicine based on this guidance is required.</s></p><p xml:id="_SnPnUzb"><s xml:id="_gD7Ckvg">Owing to the recent coronavirus disease 2019 (COVID-19) pandemic, telemedicine has rapidly and mandatorily gained recognition in Japan.</s><s xml:id="_kUQDxFZ">After the state of emergency was declared in April 2020, the MHLW has permitted the use of telemedicine from the first online consultation <ref type="bibr" target="#b4">[6,</ref><ref type="bibr" target="#b5">7]</ref>.</s><s xml:id="_raKbNJH">Since then, the proportion of hospitals or clinics that could provide telemedicine increased to 15.2% in April 2021 <ref type="bibr" target="#b6">[8]</ref>.</s><s xml:id="_3jqaCwR">The revision for medical service fee <ref type="bibr" target="#b7">[9]</ref> in 2022 that raised several telemedicine fees (but still less than the face-to-face outpatient fees) may help accelerate the widespread use of telemedicine <ref type="bibr" target="#b8">[10]</ref>.</s><s xml:id="_pAwJEmA">However, the number of conducting telemedicine in Japan remains considerably lower than that in European and North American countries <ref type="bibr" target="#b9">[11]</ref>.</s><s xml:id="_CzQUjqn">Thus, the advantages and challenges of telemedicine should be reconsidered to further promote its use.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nxAyeFj">AI/ML</head><p xml:id="_qYChvv7"><s xml:id="_cvMRHwd">AI has no single definition.</s><s xml:id="_nzXbYNM">The Japanese Society of Artificial Intelligence defined AI as something aimed to perform advanced inference accurately on a large amount of knowledge data <ref type="bibr">[12]</ref>.</s><s xml:id="_xzC9vn6">However, the concept of AI is highly diversified and still under discussion.</s><s xml:id="_apZ9bzt">Thus, when using this term, we need to pay attention to what kind of specific AI technology is referred to <ref type="bibr" target="#b10">[13]</ref> Currently, rule-based and ML are frequently used AI technology in medical sciences.</s><s xml:id="_7bPeP9w">In addition, the development of computer resources and easy access to medical big data enable us to utilize ML and its subfield, that is, deep learning, for clinical applications.</s></p><p xml:id="_W8tTAjw"><s xml:id="_CkrpPDR">One of the primary approaches for medical AI implementation today would be to leverage ML, including deep learning or reinforcement learning, as a tool to obtain the target output <ref type="bibr" target="#b10">[13]</ref>.</s><s xml:id="_b7Ccgma">In other words, medical AI aims to maximize the performance of the output as "prediction," "classification," or "generation" of diseases or data that are currently required in medicine, and numerous efforts are being made to implement it in society.</s><s xml:id="_BuacNNv">Recently, a large language model of Generative Pre-trained Transformer 3 (GPT-3) with supervised fine-tuning and reinforcement learning from human feedback as InstructGPT <ref type="bibr" target="#b11">[14]</ref> and its dialogue-optimized conversation web-console (ChatGPT) <ref type="bibr" target="#b12">[15]</ref> attracts huge attention worldwide.</s><s xml:id="_JfAH9FD">Surprisingly, the ChatGPT has already been scored at or near the passing threshold on the United States Medical Licensing Exam <ref type="bibr" target="#b13">[16]</ref>.</s><s xml:id="_x287rcg">The products applying these natural language processing models have the potential to rapidly penetrate in every aspect of medical fields soon.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kY5BasY">Web3.0/Metaverse/Blockchain</head><p xml:id="_MtzxDSH"><s xml:id="_bgX9vhH">Web3.0 is a next-generation Internet environment utilizing blockchain technology, and the metaverse supports part of this environment.</s><s xml:id="_PywpjnT">Blockchain technology is a type of database that processes and records transactions using cryptography, directly connecting terminals on information communication networks <ref type="bibr">[17]</ref>.</s><s xml:id="_QxA2Uhy">It has excellent tamper resistance for efficient monitoring and data management in clinical trials <ref type="bibr" target="#b14">[18]</ref>.</s><s xml:id="_mbcFTSY">The term "metaverse" refers to a virtual space where anyone can communicate similar to the real world and engage in economic activities involving money as both fiat currency and cryptocurrency <ref type="bibr" target="#b15">[19]</ref>.</s><s xml:id="_aRrXWcT">Metaverse uses cross reality (XR), including virtual reality (VR) as its utilization technology, and XR is becoming noteworthy in the medical field.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vYS28hf">XR</head><p xml:id="_FAPjAPe"><s xml:id="_34ugUrW">VR is a technology that creates a virtual environment through a computer, stimulating the human senses and making such an environment perceived as "reality."</s><s xml:id="_uQpqu8G"><ref type="bibr" target="#b16">[20]</ref> Currently, VR controls the visual and auditory senses, and it was often defined as an environment where the external "real" world is completely shut off by a full immersive head-mounted display (HMD).</s><s xml:id="_gZmtcHV">Similar concepts include Augmented Reality (AR) and Mixed Reality (MR), which mainly refer to real-time overlaying (for AR) or merging (for MR) of the environment and objects onto the actual reality we perceived using a see-through HMD or smartphones <ref type="bibr" target="#b16">[20]</ref>.</s><s xml:id="_cktPGak">Clearly distinguishing them is difficult; thus, a comprehensive concept of XR (cross reality or extended reality) emerged.</s><s xml:id="_76hqJMT">In the medical field, XR has already been used for medical equipment-level surgical support system <ref type="bibr" target="#b17">[21]</ref>, medical education <ref type="bibr" target="#b18">[22]</ref>, and XR-based rehabilitation system <ref type="bibr" target="#b19">[23]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_brwKByV">EHR/PHR</head><p xml:id="_uDjezvx"><s xml:id="_MEFSxtK">EHR is a collection of electronic medical records stored in an electronic chart originally intended to use only in each hospital or clinic but made shareable and accessible in a specific region or nationwide <ref type="bibr" target="#b20">[24]</ref>.</s><s xml:id="_ARTZtZs">EHR contains sensitive personal information; thus, it has been managed mainly by medical institutions.</s><s xml:id="_aWKDQW5">Conversely, the PHR refers to securely usable online medical, health, care and well-being information collected and managed by the person who is being described in the record <ref type="bibr" target="#b21">[25]</ref> In PHR, health-related information can be shared and aggregated at the individual level.</s><s xml:id="_T4Pa4JB">Thus, even if people visited multiple clinics, PHR can manage not only their medical records but also their lifelong data obtained by wearable devices during daily life.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uvruZBh">mHealth</head><p xml:id="_27t5Mgn"><s xml:id="_thC6vtT">The term "mHealth" generally refers to digital health using mobile devices.</s><s xml:id="_Q8Nt4Qu">Currently, the most used mobile devices are smartphones and wearable devices.</s><s xml:id="_xAckYK5">With the advancement of "smart" devices, mobile devices can now measure and estimate not only steps or pulse rates but also electrocardiograms, skin temperature, blood oxygen levels, stress levels, blood pressure, or plasma glucose levels <ref type="bibr" target="#b22">[26]</ref>.</s><s xml:id="_bzndBqS">The wearable devices can also be linked with smartphones to allow viewing, verifying, and processing of biometric data in detail and sharing of data with healthcare providers as needed.</s></p><p xml:id="_Umt5Gr9"><s xml:id="_Fe9Qf8c">In mHealth, DTx is attracting attention as a novel third option for disease treatment; it is one of the three core treatment pillars, namely, medical, surgical, and digital therapies.</s><s xml:id="_rdTppma">I especially focus on DTx in the following chapters.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_TnxUeNC">What is DTx?</head><p xml:id="_sfxsSYr"><s xml:id="_5SxQ2pd">DTx is a novel therapeutic option that provides treatment for illnesses through software applications (apps) delivered via digital devices <ref type="bibr" target="#b2">[4]</ref>, and is expanding its scope to disease prevention and management.</s><s xml:id="_kcD3j3Z">Currently, smartphones and VR HMDs are prevalently used for this purpose.</s><s xml:id="_KF26ZrR">This concept of DTx was introduced in Japan with the revision of the Act on Securing Quality, Efficacy, and Safety of Products Including Pharmaceuticals and Medical Devices, which demonstrated that software programs (i.e., Software as a Medical Device [SaMD]), including standalone apps themselves, could be certified as medical devices (Fig. <ref type="figure" target="#fig_0">1</ref>) <ref type="bibr">[27]</ref>.</s><s xml:id="_SU3ggHH">Currently, the software app that provides DTx is called "therapeutic apps."</s><s xml:id="_sjPJQrP">The term "prescription digital therapeutics" is also used, considering that physicians or healthcare professionals "prescribe" the therapeutic app to the patients, let them install it on their digital device, and provide the intended treatment <ref type="bibr" target="#b2">[4]</ref>.</s><s xml:id="_zehbmP7">DTx not only aims to treat illnesses but also provides a direct digital intervention to patients that have a scientifically proven treatment effect, and it has been approved by regulatory agencies.</s><s xml:id="_KNnjuX7">In addition, compared with medical care provided in hospitals or clinics, DTx can provide seamless treatment interventions through mobile digital devices even in patients' daily lives.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WuwG6et">DTx in the US and Germany</head><p xml:id="_2yXtzjX"><s xml:id="_aE2X9SB">Presently, the US and Germany are particularly leading the digital health-related policies, regulations, and their development status.</s><s xml:id="_bjjKCTU">In the US, regulation of mobile medical applications (MMAs), including DTx, was first issued by the Food and Drug Administration (FDA) in 2013, and was updated in 2015, 2019, and 2022 <ref type="bibr" target="#b23">[28]</ref>.</s><s xml:id="_jmgjmeh">Similar to traditional medical devices, MMAs that have a significant impact on patients or medical decision-making requires appropriate regulation processes, including clinical trials.</s><s xml:id="_Ft6yaDq">However, the conventional medical device approval process does not automatically adopt the rapidly evolving digital technology used in software or MMA development.</s><s xml:id="_VKvwXep">Therefore, in July 2017, the FDA launched the Digital Health Innovation Action Plan, which includes the Software Pre-Cert Pilot Program, a system used for faster and safer review and approval processes of digital health products, including MMAs <ref type="bibr" target="#b24">[29]</ref>.</s><s xml:id="_RKMSJYK">This innovative system assesses the development capabilities and safety of the development manufacturers rather than each individual medical device software, allowing the companies to bring their FDAcleared software to market faster and more efficiently.</s><s xml:id="_DBYadUy">Although the pilot program was completed in September 2022 <ref type="bibr" target="#b25">[30]</ref>, the FDA continues to develop policies with the Digital Health Center of Excellence, a digital health resource center, to improve regulatory processes related to medical device software, enabling digital health stakeholders to advance all aspects of healthcare through highquality digital health innovation <ref type="bibr">[31]</ref>.</s></p><p xml:id="_6gScpXA"><s xml:id="_HYV7N7M">Germany is releasing more DTx medical device software to the market than the US.</s><s xml:id="_Zk6PhRE">Germany installs the same public health insurance system as Japan, and the implemented policies provide important hints on how to generalize DTx and medical device software.</s><s xml:id="_PmVFY2B">In November 2019, Germany launched the Digital Healthcare Act (Digitale-Versorgung-Gesetz or DVG) <ref type="bibr" target="#b26">[32]</ref>, which explains the review and approval process of low-risk medical devices essentially based on digital technologies such as Digital Health Applications (Digitale Gesundheitsanwendungen or DiGA) <ref type="bibr" target="#b27">[33]</ref>.</s><s xml:id="_eY3V9jm">Same as FDA, the German Federal Institute for Drug and Medical Devices (Bundesinstitut fÃ¼r Arzneimittel und Medizinprodukte or BFArM) assesses DiGA according to the following requirements: safety, functionality, quality, data protection, data security, and positive effects on care under the DVG.</s><s xml:id="_V6m423D">However, the DVG's striking point is that even the DiGA and its manufacturer satisfy all requirements excluding the "positive effects on care," the DiGA can still provisionally be registered in the BFArM directory <ref type="bibr" target="#b28">[34]</ref>.</s><s xml:id="_X8zYRJ9">Therefore, even if the manufacturer has not submitted the DiGA's clinical efficacy validation data through regulation processes, such as clinical trials, the DiGA can still be registered and tentatively reimbursed by health insurance as long as the app's safety, functionality, quality, data protection, and data security are satisfactory.</s><s xml:id="_JxNpxfb">The provisional reimbursement period is limited to 12 months (or can be extended to 24 months in a specific situation) until the clinical efficacy evaluation is confirmed.</s><s xml:id="_Rkf3qJX">However, during this period, the manufacturer can conduct the DiGA's pivotal trials, or real-world data can be collected while distributing the app in the market with health insurance coverage <ref type="bibr" target="#b28">[34]</ref>.</s><s xml:id="_92eqh7G">As of February 2023, 48 DiGAs have been registered in the BFArM directory.</s><s xml:id="_F2ypTz6">Of these apps, 16 (33%) have reached permanent reimbursement, 5 (approximately 10%) were removed from the list, and 27 (56%) are in the provisional reimbursement period and are closely monitored if they can demonstrate sufficient clinical efficacy to obtain permanent reimbursement <ref type="bibr" target="#b29">[35]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YbZnKp7">DTx in Japan</head><p xml:id="_haQCNnx"><s xml:id="_tHg53Fy">DTx in Japan has been led mainly by several start-ups since 2014 when the Act on Securing Quality, Efficacy, and Safety of Products Including Pharmaceuticals and Medical Devices were revised.</s><s xml:id="_sDyYjdV">Same in the US or Germany, Japan's medical device software showing a therapeutic effect for diseases needs to be regulated by the MHLW.</s><s xml:id="_kqdrkyR">In 2020, to further promote early implementation of novel SaMD products, including DTx apps in Japan, the MHLW launched the Digital Transformation Action Strategies in Healthcare (DASH) for SaMD <ref type="bibr">[36]</ref>.</s><s xml:id="_uTMezwQ">This strategy included the following: (1) seeking promising technologies; (2) arranging and disclosing the concept of a review process specialized in SaMD; (3) centralizing the SaMD consultation service; (4) establishing a SaMD-compatible rapid, efficient, and flexible review system; and (5) reinforcing the review system for early SaMD implementation.</s><s xml:id="_72xYFvT">Such regulatory efforts to implement SaMD have improved the related guidance and guidelines <ref type="bibr" target="#b30">[37]</ref>, leading to a better environment to develop medical device software in Japan.</s></p><p xml:id="_sUxVhrU"><s xml:id="_VgYtkmz">As of February 2023, two types of DTx (for nicotine addiction [CureApp SC TM ] and for hypertension [CureApp HT TM ]) have been approved and reimbursed by the MHLW in Japan.</s><s xml:id="_FkDvfDU">Additionally, DTx for insomnia (SUSMED Med CBT-i) has newly been cleared by MHLW <ref type="bibr" target="#b31">[38]</ref>.</s><s xml:id="_SNt88SQ">The following section focuses on the two former DTx apps relating to cardiovascular medicine.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_P77favG">DTx system for nicotine dependence</head><p xml:id="_4WWNRfh"><s xml:id="_X2qUufa">The CureApp SC TM DTx for nicotine dependence is a therapeutics system that aims to provide intervention and support for psychological dependence to quit smoking in addition to the 12-week standard smoking cessation program in Japan <ref type="bibr" target="#b32">[39]</ref>.</s><s xml:id="_3AHmZRG">This DTx system consists of a smartphone therapeutic app, a Bluetooth-paired mobile checker device for exhaled carbon monoxide (CO), and a web-based personal computer software for physicians <ref type="bibr" target="#b33">[40]</ref>.</s><s xml:id="_athVxvv">It provides individually tailored behavioral therapy and quit-smoking guidance content through a therapeutic app, thereby intensifying the treatment for psychological dependence on smoking.</s><s xml:id="_v2ARHXH">Moreover, an equipped mobile CO breath analyzer allows patients to measure their expiratory CO levels daily and view their cessation progress through a smartphone app or web-based software for physicians.</s><s xml:id="_Pk5DKWg">A multicenter randomized controlled trial assessed the usefulness of the DTx for nicotine dependence <ref type="bibr" target="#b34">[41]</ref>.</s><s xml:id="_epzKS7n">A total of 584 patients diagnosed with nicotine dependence were allocated to either of the following groups: intervention group (using the DTx system for nicotine dependence in addition to a standard smoking cessation program) and control group (using a sham app in addition to a standard smoking cessation program).</s><s xml:id="_U55rJ9G">The primary outcome of the continuous abstinence rate from weeks 9 to 24 was significantly higher in the DTx intervention group than in the control group (63.9% vs. 50.5%;</s><s xml:id="_MJ7hKKx">odds ratio [OR], 1.73; 95% confidence interval [CI], 1.24-2.42,</s><s xml:id="_4WbsX2q">P = 0.001), and this DTx add-on effect continued at least up to 52 weeks.</s><s xml:id="_C6xmrWW">Hence, the DTx system for nicotine dependence significantly improved the continuous abstinence rate when added to a standard smoking cessation program.</s><s xml:id="_bwfF4hE">Based on these results, the CureApp SC TM DTx system was approved and reimbursed by the MHLW in Japan in 2020 as the first DTx in Asia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Bj2M4rY">SaMD DTx app for hypertension</head><p xml:id="_a4yA2jR"><s xml:id="_F5P9rCh">The CureApp HT TM DTx for hypertension is a SaMD therapeutic app that aims to provide continuous treatment for high blood pressure, not only during intermittent clinic visits but also in their daily life.</s><s xml:id="_bHh7MQe">This app was developed to efficiently support and maximize the blood pressurelowering effect of lifestyle modification <ref type="bibr" target="#b35">[42]</ref>, which is recommended for all patients with high blood pressure by the hypertension management guidelines <ref type="bibr" target="#b36">[43,</ref><ref type="bibr" target="#b37">44]</ref>.</s><s xml:id="_ZgAAsG2">Although many physicians think that hypertension treatment links directly to pharmacological therapy, nonpharmacological therapy has also demonstrated robust blood pressurelowering effects.</s><s xml:id="_dqPcsXm">Nonpharmacological therapy includes a low-salt diet, weight reduction, regular exercise, moderate alcohol consumption, good sleep, stress management <ref type="bibr" target="#b38">[45,</ref><ref type="bibr" target="#b39">46]</ref>.</s><s xml:id="_zaNBbWK">With this background in the algorithm, the DTx app for hypertension aims to educate, practice, and habituate each nonpharmacological therapy for patients with hypertension through the app during daily life outside hospitals or clinics.</s><s xml:id="_3Y7nKD4">The app first provides knowledge and techniques to the users for the six non-pharmacological therapy for hypertension (Step 1: input and education).</s><s xml:id="_752k9ED">Next, with the app's support, the users implement specific lifestyle modifications related to the nonpharmacological therapy based on the knowledge and techniques obtained in Step 1 (Step 2: app-supported experiences).</s><s xml:id="_PDEBwJZ">Finally, the users independently set, implement, and evaluate their own goals and achievements of lifestyle modification and truly habituate the target nonpharmacological therapy in their daily life (Step 3: self-planning evaluation) <ref type="bibr" target="#b40">[47]</ref>.</s></p><p xml:id="_bUpxaZn"><s xml:id="_jyTJ7KQ">The efficacy of DTx for hypertension was tested in the HERB-DH1 pivotal clinical trial <ref type="bibr" target="#b41">[48]</ref>.</s><s xml:id="_G4JSAwn">The trial enrolled 390 patients aged 65 years or younger who had essential hypertension (grade I or II) but were not taking antihypertensive agents; they were then allocated to either of the DTx intervention group (received the DTx app for hypertension and lifestyle modification guidance according to the guidelines) or the control group (only received lifestyle modification education according to the guidelines) <ref type="bibr" target="#b40">[47]</ref>.</s><s xml:id="_C4BWMjJ">The primary endpoint of the change in 24-hour systolic blood pressure by ambulatory blood pressure monitoring from baseline (week 0) to week 12 was -4.9 and -2.3 mmHg mmHg in the DTx intervention and control groups, respectively.</s><s xml:id="_pjRtK5p">Hence, the DTx app intervention group had a significantly greater reduction in blood pressure than the control group (mean difference, -2.4 mmHg; 95% CI, -4.5 to -0.3; P = 0.024).</s><s xml:id="_xnwuAKd">Additionally, the reduction of morning home systolic blood pressure from baseline to week 12 was greater in the DTx intervention group than in the control group (-10.6 mmHg vs. -6.2</s><s xml:id="_4TVgUbs">mmHg; mean difference, -4.3 mmHg; 95% CI, -6.7 to -1.9; P &lt; 0.001).</s><s xml:id="_fhrD5aG">Furthermore, these blood pressure reduction effects persisted at week 24 at least.</s><s xml:id="_q7pHD3d">In conclusion, the DTx for hypertension in addition to the guideline-based hypertension management was effective in patients aged 65 years or younger who had essential hypertension without antihypertensive agents.</s></p><p xml:id="_r5dTj58"><s xml:id="_8h6Dfyp">On top of that, we conducted a cost-effectiveness analysis of the DTx for hypertension by using the background characteristics and effect data of both intervention and control groups in the HERB-DH1 trial <ref type="bibr" target="#b42">[49]</ref>.</s><s xml:id="_8hVptGu">In this analysis, we examined the medical economic effects of using the therapeutic app of DTx for hypertension with a time horizon.</s><s xml:id="_SJKBUe2">The differences in medical costs and quality-adjusted life years (QALY) between the DTx intervention group and the control group were 110 717 yen (higher in the DTx intervention group) and 0.092 (longer in the app intervention group).</s><s xml:id="_qyXKKwG">Therefore, the incremental cost-effectiveness ratio (ICER) was calculated to be 1 199 880 yen/QALY <ref type="bibr" target="#b42">[49]</ref>.</s><s xml:id="_4xXRBQB">This ICER value was lower than the "willingness-to-pay" threshold of 5 million yen/QALY, which is one of the acceptable medical costs for each increase in 1 QALY.</s><s xml:id="_tKv8mXx">Thus, prescribing the DTx app might be cost-effective through life.</s><s xml:id="_Q7deQKB">Considering these series of evidence, the CureApp HT TM DTx for hypertension was cleared and was reimbursed by the MLHW in Japan as the world's first hypertension therapeutic app in 2022.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_geExDVp">Conclusions and future perspective</head><p xml:id="_5KxWzwW"><s xml:id="_fZcK83M">This review introduces the latest and various digital health technologies with specific terminologies along with the DTx in cardiovascular medicine.</s><s xml:id="_cc9jHAA">Although only three DTx apps have been approved by MHLW in Japan, several manufacturers, including DTx start-ups and pharmaceutical companies, continuously develop DTx and conduct clinical research to obtain regulatory approval.</s><s xml:id="_EpuG3X2">The number of DTx development pipelines in Japan surpasses more than 30, which continues to increase every year (Table <ref type="table">1</ref>).</s><s xml:id="_prtF4E8">The movement to promote DTx in cardiovascular medicine, which applies various digital technologies to patients with cardiovascular diseases and considers the technologies' safety, efficacy, and cost-effectiveness, will accelerate not only through basic experiments and clinical studies but also through social implementation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HECYvKS">Compliance with ethical standards</head><p xml:id="_k4byZGq"><s xml:id="_aesgTyZ">Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s><s xml:id="_UeEUtQn">The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material.</s><s xml:id="_YCQxEZE">If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_sNXP3DU">To view a copy of this license, visit <ref type="url" target="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.  org/licenses/by/4.0/</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_XfSFRuw"><s xml:id="_3DJWuG3">Fig. 1 Correlation diagram among digital health-related terminologies</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_z2nxfT7"><s xml:id="_yufF8mm">Digital health, digital medicine, and digital therapeutics in cardiology: current evidence and future. . .</s></p></note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_TVwZrTX" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<idno type="DOI">10.1016/b978-0-12-817485-2.00019-5</idno>
		<ptr target="https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health" />
		<title level="m" xml:id="_ahzQ6pU">What is Digital Health?</title>
		<imprint>
			<publisher>US Food and Drug Administration</publisher>
			<date>Feb 18</date>
		</imprint>
	</monogr>
	<note type="raw_reference">US Food and Drug Administration. What is Digital Health? https://www.fda.gov/medical-devices/digital-health-center- excellence/what-digital-health. Accessed Feb 18.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main" xml:id="_BaBDKGw">Defining Digital Medicine</title>
		<idno type="DOI">10.18261/issn1891-943x-2015-jubileumsnummer-03</idno>
		<ptr target="https://dimesociety.org/about-us/defining-digital-medicine/" />
		<imprint>
			<date>Feb 21</date>
			<publisher>Digital Medicine Society (DiME</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Digital Medicine Society (DiME). Defining Digital Medicine. https://dimesociety.org/about-us/defining-digital-medicine/. Accessed Feb 21.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<ptr target="https://dtxalliance.org/" />
		<title level="m" xml:id="_TdsTcZF">Industry overview</title>
		<imprint>
			<publisher>Digital Therapeutics Alliance</publisher>
			<date>Feb 5</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Digital Therapeutics Alliance. Industry overview. https://dtxallia nce.org/. Accessed Feb 5.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<idno type="DOI">10.1002/9780471462422.eoct344</idno>
		<ptr target="https://www.mhlw.go.jp/content/000889114.pdf" />
		<title level="m" xml:id="_edsgA99">Guidance for appropriate implementation of telemedicine</title>
		<imprint>
			<publisher>Ministry of Health Labour and Welfare in Japan</publisher>
			<date>Feb 5</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ministry of Health Labour and Welfare in Japan. Guidance for appropriate implementation of telemedicine (Japanese). https://www.mhlw.go.jp/content/000889114.pdf. Accessed Feb 5.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main" xml:id="_ycfFu7Z">Prime Minister&apos;s Office of Japan</title>
		<idno type="DOI">10.1163/2210-7975_hrd-0188-0049</idno>
		<ptr target="https://japan.kantei.go.jp/ongoingtopics/_00018.html" />
		<imprint>
			<date>Feb 20</date>
		</imprint>
	</monogr>
	<note>Declaration of a State of Emergency in response to the Novel Coronavirus Disease (April 7)</note>
	<note type="raw_reference">Prime Minister&apos;s Office of Japan. [COVID-19] Declaration of a State of Emergency in response to the Novel Coronavirus Disease (April 7). https://japan.kantei.go.jp/ongoingtopics/_00018.html. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<author>
			<persName><forename type="first">K</forename><surname>Noto</surname></persName>
		</author>
		<author>
			<persName><surname>Apco Worldwide</surname></persName>
		</author>
		<ptr target="https://apcoworldwide.com/blog/the-challenges-and-growth-of-telehealth-in-japan/" />
		<title level="m" xml:id="_PAUcWFX">The Challenges and Growth of Telehealth in Japan: Is it here to stay?</title>
		<imprint>
			<date>Feb 20</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Noto K, APCO worldwide. The Challenges and Growth of Tel- ehealth in Japan: Is it here to stay? https://apcoworldwide.com/ blog/the-challenges-and-growth-of-telehealth-in-japan/. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<ptr target="https://www.soumu.go.jp/johotsusintokei/whitepaper/eng/WP2021/chapter-2.pdf#page=4" />
		<title level="m" xml:id="_Gsx9Sh9">Digitalization Accelerated by the COVID-19 Pandemic</title>
		<imprint>
			<publisher>WHITE PAPER</publisher>
			<date type="published" when="2021-02-20">2021. Feb 20</date>
		</imprint>
	</monogr>
	<note>Chapter 2</note>
	<note type="raw_reference">Ministry of Internal Affairs and Communications in Japan. Information and Communications in Japan (WHITE PAPER 2021). Chapter 2. Digitalization Accelerated by the COVID-19 Pandemic. https://www.soumu.go.jp/johotsusintokei/whitepaper/ eng/WP2021/chapter-2.pdf#page=4. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main" xml:id="_SnbpQnu">2 The Medical Service Fee System</title>
		<ptr target="https://japanhpn.org/en/section-7-2/" />
		<imprint>
			<date>Feb 20</date>
			<publisher>Japan Health Policy Now (Health and Global Policy Institute</publisher>
			<biblScope unit="volume">7</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Japan Health Policy Now (Health and Global Policy Institute). 7.2 The Medical Service Fee System. https://japanhpn.org/en/section- 7-2/. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<idno type="DOI">10.28920/dhm51.4.338-344</idno>
		<ptr target="https://www.tokyo.med.or.jp/29014" />
		<title level="m" xml:id="_j23MCpA">Summary of a questionnair survey regarding telemedicine</title>
		<imprint>
			<date>Feb 20</date>
		</imprint>
		<respStmt>
			<orgName>Tokyo Medical Association</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Tokyo Medical Association. Summary of a questionnair survey regarding telemedicine (Japanese). https://www.tokyo.med.or.jp/ 29014. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<idno type="DOI">10.1787/d46e9a02-en</idno>
		<ptr target="https://www.oecd.org/coronavirus/policy-responses/the-future-of-telemedicine-after-covid-19-d46e9a02/" />
		<title level="m" xml:id="_65qhDPB">The future of telemedicine after COVID-19</title>
		<imprint>
			<publisher>OECD</publisher>
			<date>Feb 20</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Organisation for Economic Co-operation and Development (OECD). The future of telemedicine after COVID-19. https://www.oecd.org/coronavirus/policy-responses/the-future-of- telemedicine-after-covid-19-d46e9a02/. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_3HB7TPt">Artificial Intelligence in Current Diabetes Management and Prediction</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kometani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoneda</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11892-021-01423-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fqcE8Na">Curr Diab Rep</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">61</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nomura A, Noguchi M, Kometani M, Furukawa K, Yoneda T. Artificial Intelligence in Current Diabetes Management and Pre- diction. Curr Diab Rep. 2021;21:61.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main" xml:id="_3246UgJ">Training language models to follow instructions with human feedback</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ouyang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Wainwright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mishkin</surname></persName>
		</author>
		<idno type="DOI">10.48550/arXiv.2203.02155</idno>
		<ptr target="https://doi.org/10.48550/arXiv.2203.02155" />
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ouyang L, Wu J, Jiang X, Almeida D, Wainwright CL, Mishkin P, et al. Training language models to follow instructions with human feedback. 2022. https://doi.org/10.48550/arXiv.2203. 02155.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Open</surname></persName>
		</author>
		<ptr target="https://openai.com/blog/chatgpt/" />
		<title level="m" xml:id="_2ZEc88M">ChatGPT: Optimizing Langeuage Models for Dialogue</title>
		<imprint>
			<date>Feb 20</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Open AI. ChatGPT: Optimizing Langeuage Models for Dialogue. https://openai.com/blog/chatgpt/. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_FYfvUKN">Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cheatham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Medenilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sillos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>ElepaÃ±o</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pdig.0000198</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XBGqVvE">PLOS Digit Health</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e0000198</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kung TH, Cheatham M, Medenilla A, Sillos C, De Leon L, ElepaÃ±o C, et al. Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models. PLOS Digit Health. 2023;2:e0000198.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_RZkuEPf">Secure and Scalable mHealth Data Management Using Blockchain Combined With Client Hashchain: System Design and Validation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Motohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hirano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kashiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ichikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jwaM5Yw">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">13385</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Motohashi T, Hirano T, Okumura K, Kashiyama M, Ichikawa D, Ueno T. Secure and Scalable mHealth Data Management Using Blockchain Combined With Client Hashchain: System Design and Validation. J Med Internet Res. 2019;21:e13385.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<author>
			<persName><forename type="first">S</forename><surname>Kubota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ishimura</surname></persName>
		</author>
		<title level="m" xml:id="_BRnEX9s">Metaverse Future Strategy</title>
		<imprint>
			<publisher>Nikkei BP</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>Japanese</note>
	<note type="raw_reference">Kubota S, Ishimura N. Metaverse Future Strategy (Japanese). Nikkei BP, 2022.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_3My95An">Applying Modern Virtual and Augmented Reality Technologies to Medical Images and Models</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sutherland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Belec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sheikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chepelev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Althobaity</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bjw</forename><surname>Chow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kfTsGc7">J Digit Imaging</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="38" to="53" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sutherland J, Belec J, Sheikh A, Chepelev L, Althobaity W, Chow BJW, et al. Applying Modern Virtual and Augmented Reality Technologies to Medical Images and Models. J Digit Imaging. 2019;32:38-53.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_RzgAtvM">Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kitagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marukuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hara</surname></persName>
		</author>
		<idno type="DOI">10.21873/anticanres.15990</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DdM9MHc">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="4849" to="4856" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ryu S, Kitagawa T, Goto K, Okamoto A, Marukuchi R, Hara K, et al. Intraoperative Holographic Guidance Using Virtual Reality and Mixed Reality Technology During Laparoscopic Colorectal Cancer Surgery. Anticancer Res. 2022;42:4849-56.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_AwkTr8P">Virtual reality as a learning tool for improving infection control procedures</title>
		<author>
			<persName><forename type="first">K</forename><surname>Omori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shigemoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kitagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kaiki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miyaji</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajic.2022.05.023</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eBfe6QV">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="129" to="134" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, et al. Virtual reality as a learning tool for improving infection control procedures. Am J Infect Control. 2023;51:129-34.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_vCayHvN">Safety and Feasibility of Dual-task Rehabilitation Program for Body Trunk Balance Using Virtual Reality and Three-dimensional Tracking Technologies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kitamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Murakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shimba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tamaki</surname></persName>
		</author>
		<idno type="DOI">10.2490/prm.20180016</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_chYf44r">Prog Rehabil Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">20180016</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hara M, Kitamura T, Murakawa Y, Shimba K, Yamaguchi S, Tamaki M. Safety and Feasibility of Dual-task Rehabilitation Program for Body Trunk Balance Using Virtual Reality and Three-dimensional Tracking Technologies. Prog Rehabil Med. 2018;3:20180016.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_jbbk7V5">The emergence of national electronic health record architectures in the United States and Australia: models, costs, and questions</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Gunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Terry</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.7.1.e3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q3rCFMp">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e3</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gunter TD, Terry NP. The emergence of national electronic health record architectures in the United States and Australia: models, costs, and questions. J Med Internet Res. 2005;7:e3.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<idno type="DOI">10.3403/30238273u</idno>
		<ptr target="https://digital.nhs.uk/services/personal-health-records-adoption-service/personal-health-records-adoption-toolkit/initiating-a-personal-health-record/personal-health-records-definition" />
		<title level="m" xml:id="_23Z9xye">Personal Health Records definition</title>
		<imprint>
			<publisher>National Health Service Digital</publisher>
			<date>Feb 20</date>
		</imprint>
	</monogr>
	<note type="raw_reference">National Health Service Digital. Personal Health Records definition. https://digital.nhs.uk/services/personal-health-records-adoption- service/personal-health-records-adoption-toolkit/initiating-a-persona l-health-record/personal-health-records-definition. Accessed Feb 20.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_dFC5CZv">The Impact of Wearable Technologies in Health Research: Scoping Review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Huhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Axt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gunga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Munga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Obor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gFtkPDZ">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">34384</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huhn S, Axt M, Gunga HC, Maggioni MA, Munga S, Obor D, et al. The Impact of Wearable Technologies in Health Research: Scoping Review. JMIR Mhealth Uhealth. 2022;10:e34384.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main" xml:id="_aXeNUuE">Device Software Functions Including Mobile Medical Applications</title>
		<idno type="DOI">10.1016/b978-0-323-95354-2.00011-6</idno>
		<ptr target="https://www.fda.gov/medical-devices/digital-health-center-excellence/device-software-functions-including-mobile-medical-applications" />
		<imprint>
			<date>Feb 15</date>
			<publisher>US Food and Drug Administration</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">US Food and Drug Administration. Device Software Functions Including Mobile Medical Applications. https://www.fda.gov/ medical-devices/digital-health-center-excellence/device-software- functions-including-mobile-medical-applications. Accessed Feb 15.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<idno type="DOI">10.1037/e310612004-001</idno>
		<ptr target="https://www.fda.gov/media/106331/download" />
		<title level="m" xml:id="_tgRYbsc">Digital Health Innovation Action Plan</title>
		<imprint>
			<publisher>US Food and Drug Administration</publisher>
			<date>Feb 18</date>
		</imprint>
	</monogr>
	<note type="raw_reference">US Food and Drug Administration. Digital Health Innovation Action Plan. https://www.fda.gov/media/106331/download. Accessed Feb 18.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<ptr target="https://www.fda.gov/media/161815/download" />
		<title level="m" xml:id="_Hg4bckV">The Software Precertification (Pre-Cert) Pilot Program: Tailored Total Product Lifecycle Approaches and Key Findings</title>
		<imprint>
			<date>Feb 18</date>
		</imprint>
		<respStmt>
			<orgName>US Food and Drug Administration</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">US Food and Drug Administration. The Software Precertification (Pre-Cert) Pilot Program: Tailored Total Product Lifecycle Approaches and Key Findings. https://www.fda.gov/media/ 161815/download. Accessed Feb 18.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<idno type="DOI">10.1007/978-3-030-94025-6_2</idno>
		<ptr target="https://www.bundesgesundheitsministerium.de/en/digital-healthcare-act.html" />
		<title level="m" xml:id="_MqfFhgU">Driving the digital transformation of Germany&apos;s healthcare system for the good of patients</title>
		<imprint>
			<publisher>Federal Ministry of Health in Germany</publisher>
			<date>Feb 18</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Federal Ministry of Health in Germany. Driving the digital transformation of Germany&apos;s healthcare system for the good of patients. https://www.bundesgesundheitsministerium.de/en/digita l-healthcare-act.html. Accessed Feb 18.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<idno type="DOI">10.1016/j.jval.2024.10.2197</idno>
		<ptr target="https://www.bfarm.de/EN/Medical-devices/Tasks/DiGA-and-DiPA/Digital-Health-Applications/_node.html" />
		<title level="m" xml:id="_2cneDwS">DiGA Digital Health Applications</title>
		<imprint>
			<publisher>Federal Institute for Drugs and Medical Devices in Germany</publisher>
			<date>Feb 19</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Federal Institute for Drugs and Medical Devices in Germany. DiGA Digital Health Applications. https://www.bfarm.de/EN/ Medical-devices/Tasks/DiGA-and-DiPA/Digital-Health-Applica tions/_node.html. Accessed Feb 19.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_KTaFFdE">Germany&apos;s digital health reforms in the COVID-19 era: opportunities for other countries</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gerke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Stern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Minssen</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-020-0306-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NtjjNmt">NPJ Digit Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">94</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerke S, Stern AD, Minssen T. Germany&apos;s digital health reforms in the COVID-19 era: opportunities for other coun- tries. NPJ Digit Med. 2020;3:94.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_M2cpHEJ">and Medical Devices in Germany</title>
		<idno type="DOI">10.9785/gesr-2020-191103</idno>
		<ptr target="https://diga.bfarm.de/de/verzeichnis" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_FCx2yeW">DiGA directory</title>
		<imprint>
			<date>Feb 19</date>
		</imprint>
		<respStmt>
			<orgName>Federal Institute for Drugs</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Federal Institute for Drugs and Medical Devices in Germany. DiGA directory. https://diga.bfarm.de/de/verzeichnis. Accessed Feb 19.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<ptr target="https://md-guidelines.pj.aist.go.jp/wp-content/uploads/2022/05/65_guideline_draft.pdf" />
		<title level="m" xml:id="_jDCgrnD">Guideline for medical device software encouraging behavior change in health and care</title>
		<imprint>
			<publisher>Ministry of Health Labour and Welfare in Japan</publisher>
			<date>Feb 21</date>
		</imprint>
	</monogr>
	<note>Draft) (Japanese</note>
	<note type="raw_reference">Ministry of Health Labour and Welfare in Japan. Guideline for medical device software encouraging behavior change in health and care (Draft) (Japanese). https://md-guidelines.pj.aist.go.jp/wp- content/uploads/2022/05/65_guideline_draft.pdf. Accessed Feb 21.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_r5ncwnq">Effect of Smartphone-based Cognitive Behavioral Therapy App on Insomnia: a Randomized, Double-blind Study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuroki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ichikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ozone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Uchimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueno</surname></persName>
		</author>
		<idno type="DOI">10.1093/sleep/zsac270</idno>
		<ptr target="https://doi.org/10.1093/sleep/zsac270)" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8NDv5wP">Sleep</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Watanabe Y, Kuroki T, Ichikawa D, Ozone M, Uchimura N, Ueno T Effect of Smartphone-based Cognitive Behavioral Therapy App on Insomnia: a Randomized, Double-blind Study. Sleep. 2022. https://doi.org/10.1093/sleep/zsac270).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<idno type="DOI">10.1253/circj.cj-66-0062</idno>
		<ptr target="http://j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev8_.pdf" />
		<title level="m" xml:id="_Ky2T5P8">The Standard Procedure Manual for Smoking Cessation</title>
		<imprint>
			<publisher>The Japanese Respiratory Society</publisher>
			<date>Feb 13</date>
		</imprint>
	</monogr>
	<note>8th edition</note>
	<note type="raw_reference">The Japanese Circulation Society, The Japan Lung Cancer Society, The Japanese Cancer Society, The Japanese Respiratory Society. The Standard Procedure Manual for Smoking Cessation, 8th edition. http://j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_ smoke_std_rev8_.pdf. Accessed Feb 13.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_RBhPHFw">A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tateno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Masaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Muto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Satake</surname></persName>
		</author>
		<idno type="DOI">10.2196/12252</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pnepPam">JMIR Res Protoc</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e12252</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nomura A, Tateno H, Masaki K, Muto T, Suzuki S, Satake K, et al. A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2019;8:e12252.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_2xY5akD">A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker</title>
		<author>
			<persName><forename type="first">K</forename><surname>Masaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tateno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Muto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Satake</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-020-0243-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bCXtEjg">NPJ Digit Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">35</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Masaki K, Tateno H, Nomura A, Muto T, Suzuki S, Satake K, et al. A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker. NPJ Digit Med. 2020;3:35.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_KGcrhfy">Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>So</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.14191</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4exNCv6">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="923" to="934" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Nomura A, Kato A, Harada N, Tanigawa T, So R, et al. Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study. J Clin Hypertens. 2021;23:923-34.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_jmUD7AN">The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Umemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dohi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hirooka</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-019-0284-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9wbDpkF">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1235" to="1481" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235-481.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_UWFCuee">International Society of Hypertension Global Hypertension Practice Guidelines</title>
		<author>
			<persName><forename type="first">T</forename><surname>Unger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Borghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Charchar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Poulter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Prabhakaran</surname></persName>
		</author>
		<idno type="DOI">10.1161/hypertensionaha.120.15026</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kuzJS2X">Hypertension</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1334" to="1357" />
			<date type="published" when="2020">2020. 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabha- karan D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334-57.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_xd7d5pn">Non-pharmacological management of hypertension: in the light of current research</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mahmood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">U</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nawaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rashid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Swa</forename><surname>Baqar</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11845-018-1889-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uXkGbdC">Ir J Med Sci</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="437" to="452" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mahmood S, Shah KU, Khan TM, Nawaz S, Rashid H, Baqar SWA, et al. Non-pharmacological management of hypertension: in the light of current research. Ir J Med Sci. 2019;188:437-52.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_fBD2U6k">Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Quan</surname></persName>
		</author>
		<idno type="DOI">10.1161/jaha.120.016804</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kgVQH9m">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">16804</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fu J, Liu Y, Zhang L, Zhou L, Li D, Quan H, et al. Non- pharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension. J Am Heart Assoc. 2020;9:e016804.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_xTxpepr">A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>So</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13993</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZR3242X">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1713" to="1722" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Nomura A, Harada N, Tanigawa T, So R, Nakagawa K, et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. J Clin Hypertens. 2020;22:1713-22.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_qEABSUH">Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kaFp2kd">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="4111" to="4122" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al. Efficacy of a digital therapeutics system in the manage- ment of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J. 2021;42:4111-22.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_3kNMRh2">Cost-effectiveness of digital therapeutics for essential hypertension</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Igarashi</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-022-00952-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hCCbAdr">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1538" to="1548" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45:1538-48.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
